{"id":10170,"date":"2012-04-22T09:20:57","date_gmt":"2012-04-22T09:20:57","guid":{"rendered":"http:\/\/cardiophile.org\/?p=6948"},"modified":"2012-04-22T09:20:57","modified_gmt":"2012-04-22T09:20:57","slug":"rivaroxaban-found-beneficial-for-patients-with-acs-2-2","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\/","title":{"rendered":"Rivaroxaban found beneficial for patients with ACS"},"content":{"rendered":"

Rivaroxaban found beneficial for patients with ACS<\/span><\/h2>\n

Rivaroxaban<\/a> found beneficial for patients with ACS: Jessica L Mega, Eugene Braunwald, Stephen D Wiviott, Jean-Pierre Bassand, Deepak L Bhatt, Christoph Bode, Paul Burton, Marc Cohen, Nancy Cook-Bruns, Keith A A Fox, Shinya Goto, Sabina A Murphy, Alexei N Plotnikov, David Schneider, Xiang Sun, Freek W A Verheugt and C Michael Gibson the ATLAS ACS 2\u2013TIMI 51 (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome 2\u2013Thrombolysis in Myocardial Infarction 51) Investigators [1] evaluated the role of factor Xa inhibitor rivaroxaban in acute coronary syndrome (ACS).<\/p>\n

It was a double blind placebo controlled trial involving more than fifteen thousand and five hundred patients. Rivaroxaban was used in doses of 2.5 mg or 5 mg twice daily with a mean follow up of thirteen months. Composite of death from cardiovascular causes, myocardial infarction, or stroke was the primary efficacy endpoint. They concluded that rivaroxaban reduced the risk of composite endpoint in ACS, but increased the risk of major bleeding and intracranial hemorrhage, though not the risk of fatal bleeding.<\/p>\n

Reference<\/span><\/strong><\/p>\n

    \n
  1. Jessica L Mega, Eugene Braunwald, Stephen D Wiviott, Jean-Pierre Bassand, Deepak L Bhatt, Christoph Bode, Paul Burton, Marc Cohen, Nancy Cook-Bruns, Keith A A Fox, Shinya Goto, Sabina A Murphy, Alexei N Plotnikov, David Schneider, Xiang Sun, Freek W A Verheugt, C Michael Gibson, ATLAS ACS 2\u2013TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome<\/a>. N Engl J Med. 2012 Jan 5;366(1):9-19.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Rivaroxaban reduced the risk of composite endpoint in ACS, but increased risk of major bleeding and intracranial hemorrhage, though not fatal bleeding.<\/p>\n","protected":false},"author":1,"featured_media":36064,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-10170","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"\nRivaroxaban found beneficial for patients with ACS<\/title>\n<meta name=\"description\" content=\"Rivaroxaban found beneficial for patients with ACS: Rivaroxaban reduced the risk of composite endpoint in ACS, but increased risk of major bleeding.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rivaroxaban found beneficial for patients with ACS\" \/>\n<meta property=\"og:description\" content=\"Rivaroxaban found beneficial for patients with ACS: Rivaroxaban reduced the risk of composite endpoint in ACS, but increased risk of major bleeding.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2012-04-22T09:20:57+00:00\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Rivaroxaban found beneficial for patients with ACS\",\"datePublished\":\"2012-04-22T09:20:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\\\/\"},\"wordCount\":249,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\\\/\",\"name\":\"Rivaroxaban found beneficial for patients with ACS\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2012-04-22T09:20:57+00:00\",\"description\":\"Rivaroxaban found beneficial for patients with ACS: Rivaroxaban reduced the risk of composite endpoint in ACS, but increased risk of major bleeding.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\\\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rivaroxaban found beneficial for patients with ACS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rivaroxaban found beneficial for patients with ACS","description":"Rivaroxaban found beneficial for patients with ACS: Rivaroxaban reduced the risk of composite endpoint in ACS, but increased risk of major bleeding.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\/","og_locale":"en_US","og_type":"article","og_title":"Rivaroxaban found beneficial for patients with ACS","og_description":"Rivaroxaban found beneficial for patients with ACS: Rivaroxaban reduced the risk of composite endpoint in ACS, but increased risk of major bleeding.","og_url":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2012-04-22T09:20:57+00:00","author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Rivaroxaban found beneficial for patients with ACS","datePublished":"2012-04-22T09:20:57+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\/"},"wordCount":249,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\/#primaryimage"},"thumbnailUrl":"","articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\/","url":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\/","name":"Rivaroxaban found beneficial for patients with ACS","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\/#primaryimage"},"thumbnailUrl":"","datePublished":"2012-04-22T09:20:57+00:00","description":"Rivaroxaban found beneficial for patients with ACS: Rivaroxaban reduced the risk of composite endpoint in ACS, but increased risk of major bleeding.","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-found-beneficial-for-patients-with-acs-2-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Rivaroxaban found beneficial for patients with ACS"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/10170","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=10170"}],"version-history":[{"count":0,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/10170\/revisions"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=10170"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=10170"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=10170"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}